Üner, BurcuÖzdemir, SametTaş, ÇetinÖzsoy, YıldızÜner, Melike2022-05-242022-05-242022Üner, B., Özdemir, S., Taş, Ç., Özsoy, Y., & Üner, M.. (2022). Development of lipid nanoparticles for transdermal loteprednol etabonate delivery. Journal of Microencapsulation, 39(4), pp. 327-340. https://doi.org/10.1080/02652048.2022.2079744https://doi.org/10.1080/02652048.2022.2079744https://hdl.handle.net/20.500.13055/218Aim Loteprednol etabonate (LE) is a new generation corticosteroid that is used for the treatment of inflammatory and allergic conditions of the eye. Therefore, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were attempted to improve for transdermal LE delivery for the first time. Methods SLN and NLC were produced by hot homogenization and ultrasonication technique. Their physical stability was monitored for 3 months of storage. Drug release and permeation of SLN and NLC through the porcine skin were investigated. Results It was determined that SLN and NLC mean particle size as 139.1 nm had a homogeneous particle size distribution (∼0,169 PI) and mean charge as -23.6. They were found to be stable both physically and chemically at room temperature. Conclusion SLN and NLC formulations of LE can be stated among the systems that can be an alternative to conventional systems with less side-effect in the treatment of inflammatory problems.eninfo:eu-repo/semantics/closedAccessLoteprednol EtabonateNanostructured Lipid CarriersSolid Lipid NanoparticlesTopical CorticosteroidsTransdermal DeliveryArticle10.1080/02652048.2022.2079744394340327Q2WOS:0008046818000012-s2.0-85131358899PMID: 35583383Q2